Technology ID

Multichannel Individualized Seizure Therapy (MIST) Device

Lead Inventor
Deng, Zhi-De (NIMH)
Dold, George (NIMH)
Kim, Junghee (National Institute of Mental Health (NIMH))
Lisanby, Sarah (National Institute of Mental Health (NIMH))
Pritchard, Bruce (National Institute of Mental Health (NIH/NIMH))
Schor, Robert (NIMH)
Medical Devices
Therapeutic Areas
Psychiatry/Mental Health
Development Stages
Lead IC

The Multichannel Individualized Stimulation Therapy (MIST) device is a multichannel electrical stimulation system that can be used for targeted, individualized electroconvulsive therapy (ECT), especially for treatment-resistant depression (TRD). Millions of individuals suffer from TRD, for which ECT is often the most efficacious and rapidly acting treatment option.

Present clinical ECT devices use a single-channel to deliver strong electric fields broadly distributed throughout brain, producing significant memory loss and variability in clinical outcomes. These challenges result in the underutilization of this highly effective treatment. MIST is the first multichannel ECT device to address these limitations by delivering flexible and multi- focal stimulation, which has the potential to maximize clinical efficacy and minimize side effects. Thus, the technology represents a much more desirable method for delivering seizure therapy for those suffering from severe depression, which affects over 280 million people worldwide, and other serious disorders.

Commercial Applications
    Treatment of a broad range of clinical disorders for which ECT has shown efficacy, including:
  • Treatment Resistant Depression (TRD)
  • Major Depressive Episode associated with major depressive disorder (MDD) or bipolar disorder (BP)
  • Catatonia
  • Schizophrenia
  • Schizoaffective disorder
  • Schizophreniform disorder
  • Status epilepticus
Competitive Advantages
    Only known multichannel ECT system that:
  • Delivers flexible and multi-focal stimulation to optimally target brain structures
  • Uses targeted stimulation to mediate antidepressant action of ECT, while reducing cognitive side effects
  • Uses computational models to inform personalized dosing that greatly reduces erratic ECT clinical outcome by accounting for inter-individual anatomical variability (provides an advantage over conventional fixed current-amplitude dosing)
    Licensing Contact: